{
  "ticker": "LLY",
  "target_date": "2025-06-27",
  "actual_date": "2025-06-27",
  "collected_at": "2025-12-08T11:56:54.470171",
  "price": {
    "open": 792.89,
    "high": 799.57,
    "low": 771.81,
    "close": 772.6159057617188,
    "volume": 4115100,
    "change_1d_pct": -2.47,
    "change_7d_pct": -2.0,
    "change_30d_pct": 8.59
  },
  "technicals": {
    "rsi_14": 51.76,
    "sma_20": 777.95,
    "sma_50": 778.05,
    "macd": 4.989,
    "macd_signal": 5.35,
    "macd_histogram": -0.362,
    "bb_upper": 823.88,
    "bb_lower": 732.01,
    "price_vs_sma20_pct": -0.69,
    "price_vs_sma50_pct": -0.7,
    "volume_ratio": 1.22
  },
  "fundamentals": {
    "market_cap": 892628893696,
    "pe_ratio": 48.786377,
    "forward_pe": 43.94219,
    "price_to_book": 37.489834,
    "price_to_sales": 15.022415,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.46,
    "pct_from_52w_low": 59.63
  },
  "macro": {
    "spy": {
      "price": 613.21,
      "change_1d_pct": 0.5,
      "change_7d_pct": 3.23
    },
    "vix": {
      "level": 16.32,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.28
    },
    "dollar_index": {
      "level": 97.4
    },
    "gold": {
      "price": 3273.7
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "source": "MarketWatch",
      "datetime": 1751041860,
      "summary": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a3887d301d4f1ba9aa24dc1cb5fa060c60ebc74b66451a406419b6588c35fc64"
    },
    {
      "headline": "NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?",
      "source": "Yahoo",
      "datetime": 1751037000,
      "summary": "Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.",
      "url": "https://finnhub.io/api/news?id=83a9dfcf4baba78030c6c36e02aea81abd8906aa1c2b7aea54680dea42767ae1"
    },
    {
      "headline": "Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?",
      "source": "Yahoo",
      "datetime": 1751033400,
      "summary": "Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.",
      "url": "https://finnhub.io/api/news?id=773e8df99e9f10d590e3ccd24d0d5cac94d2f98a2363ec640dd5a3421d8881c0"
    },
    {
      "headline": "AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock",
      "source": "Yahoo",
      "datetime": 1751033280,
      "summary": "ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.",
      "url": "https://finnhub.io/api/news?id=baa8826a79472663e04428bdc72eb6478bed7a2639bca8a8adfa9faf0baa12eb"
    },
    {
      "headline": "BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside",
      "source": "Yahoo",
      "datetime": 1751032383,
      "summary": "Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly\u2019s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is expected to close in the third quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=639c5410639c3d6150a6955ca1c349666893774388e3e6c49f5701bc6f91b54c"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199300.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000176/xslF345X05/wk-form4_1750199300.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199159.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000174/xslF345X05/wk-form4_1750199159.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198988.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000172/xslF345X05/wk-form4_1750198988.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198711.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000170/xslF345X05/wk-form4_1750198711.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198504.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000168/xslF345X05/wk-form4_1750198504.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}